ClinicalTrials.gov record

Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

ClinicalTrials.gov ID: NCT02587520

Public ClinicalTrials.gov record NCT02587520. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was a dose and formulation ranging study to assess the safety and immunogenicity of SP0173 in healthy adolescents, adults, and older adults in the United States (US). Primary Objective * To describe the safety profile of each SP0173 investigational formulation. Observational Objective: * To describe the immunogenicity of each SP0173 investigational formulation.

Study identification

NCT ID: NCT02587520
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Enrollment: 1,363 participants

Conditions and interventions

Conditions

Interventions

Biological

Eligibility (public fields only)

Age range: 10 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 21, 2015
Primary completion: Feb 20, 2017
Completion: Feb 20, 2017
Last update posted: Mar 22, 2022

2015 – 2017

United States locations

U.S. sites: 20
U.S. states: 15
U.S. cities: 19

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35205	—
Not listed	Fayetteville	Arkansas	72703	—
Not listed	Jonesboro	Arkansas	72401	—
Not listed	San Diego	California	92108	—
Not listed	DeLand	Florida	32720	—
Not listed	Miami	Florida	33143	—
Not listed	Orlando	Florida	32806	—
Not listed	Meridian	Idaho	83642	—
Not listed	Bardstown	Kentucky	40004	—
Not listed	Nicholasville	Kentucky	40356	—
Not listed	Lincoln	Nebraska	68516	—
Not listed	Las Vegas	Nevada	89109	—
Not listed	Albuquerque	New Mexico	87108	—
Not listed	Rochester	New York	14609	—
Not listed	Cleveland	Ohio	44122	—
Not listed	Erie	Pennsylvania	16505	—
Not listed	Mt. Pleasant	South Carolina	29464	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Salt Lake City	Utah	84109	—
Not listed	Salt Lake City	Utah	84121	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02587520, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 22, 2022 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02587520 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →